#United States #New York #Pomerantz LLP #Viking Therapeutics #VK2735

Overview of the Investigation

On December 27, 2024, Pomerantz Law Firm announced an investigation into Viking Therapeutics, Inc. (NASDAQ: VKTX) on behalf of its investors. This attention comes amid allegations of possible securities fraud and other illegal business practices conducted by the company's officers and directors. The firm has encouraged affected investors to reach out for more information.

Recent Developments at Viking Therapeutics

The primary catalyst for the investigation stems from Viking's recent report on November 3, 2024, during the Obesity Week medical meeting. The company unveiled promising trial results for its anti-obesity medication, VK2735. Following this announcement, Viking’s stock experienced a notable increase, soaring by 9% during intraday trading on November 4, 2024. Analysts, however, quickly noted a potential downside. Concerns were raised surrounding the challenges in manufacturing VK2735, particularly regarding higher dosage forms. Deutsche Bank highlighted in their analysis that scaling up production would be a complex and expensive undertaking, requiring capital and expertise that major industry players like Eli Lilly and Novo Nordisk might struggle to provide.

Impact on Stock and Investor Sentiment

The reaction from analysts created a significant ripple effect, leading to a steep decline in Viking's stock price. On the trading day following the positive trial data, shares plummeted $9.74, representing a decrease of 13.36%, with the closing price settling at $63.14 per share. Such volatility in stock prices, particularly following a period of optimism, presents additional concern regarding the company's business practices. Investors are advised to stay vigilant and informed, as developments unfold.

Pomerantz LLP: A Leader in Securities Class Actions

Pomerantz LLP, with a longstanding reputation in corporate and securities class litigation, has been at the forefront of various high-profile investigations and claims. Founded over 85 years ago by Abraham L. Pomerantz, the firm has successfully recovered billions of dollars for victims of securities fraud and other corporate malfeasance. With offices in major cities globally, including New York, Chicago, London, and Paris, Pomerantz continues to advocate for investors' rights in an ever-evolving financial landscape.

How Investors Can Act

Affected investors of Viking Therapeutics are urged to reach out to Pomerantz LLP directly, as the firm looks to gather information for potential class actions and to arm investors with the necessary resources to counteract stated grievances. Interested parties can contact Danielle Peyton via email at [email protected] or by phone at 646-581-9980, ext. 7980 directly.

Conclusion

The investigation into Viking Therapeutics underscores the importance of transparency and accountability among publicly traded companies. Investors must remain informed about the companies in which they hold stock, especially when faced with circumstances that could impact their financial interests. As the situation with Viking progresses, it remains crucial for stakeholders to stay engaged for timely updates on potential legal actions and necessary responses.